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The optic neuritis treatment trial (ONTT) and subsequent studies have had a tremendous
impact on the treatment and prognosis of optic neuritis and multiple sclerosis in adults.
The results of these studies have been extrapolated to children; however, pediatric data
are sparse. Using the method of prospective preference assessment, the willingness of
parents and medical professionals to enroll children in a hypothetical Pediatric ONTT was
assessed using a mock consent form and questionnaire. A three-arm trial was proposed:
(1) intravenous corticosteroids, (2) high-dose oral corticosteroids, and (3) an oral placebo.
The forms were completed by 198 parents and 49 physicians.After reviewing the hypothet-
ical scenario, trial design, risks and beneﬁts, and alternatives to the study, 21% of parents
would enroll their children in the trial whereas 98% of medical professionals would enroll
their patients. With medical professional recommendation, 43% of parents would enroll
their children.The manner in which this hypothetical trial was presented to parents, specif-
ically with respect to the recommendation of their child’s health care team, inﬂuenced a
parent’s willingness to participate.
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INTRODUCTION
Optic neuritis is an acute, inﬂammatory disease of the optic
nerve and is often the initial manifestation of multiple sclero-
sis (MS) in adults and children (Duquette et al., 1987; Sindern
et al.,1992; Boiko et al.,2002; Optic Neuritis Study Group,2008a;
Bonhomme et al., 2009). The clinical proﬁle may include sudden
visionloss,dyschromatopsia,painwitheyemovements,andvisual
ﬁeld defects (Optic Neuritis Study Group,1991;Beck et al.,1992).
Recoveryoftenoccursoverthecourseof severalmonths;however,
patients may have long-lasting symptoms of visual impairment
(Sanders et al., 1986; Fleishman et al., 1987; Beck and Cleary,
1993). Even if visual acuity returns to baseline, abnormalities in
colorvision,visualﬁeld,andcontrastsensitivitymaypersist(Optic
Neuritis Study Group, 2008b).
In adults,the optic neuritis treatment trial (ONTT) has shown
that the administration of intravenous corticosteroids hastens
visual recovery,but does not affect the long-term visual or neuro-
logic prognosis when compared to placebo (Optic Neuritis Study
Group, 2008b). Despite insufﬁcient evidence in the pediatric age
groupof long-termefﬁcacyandthepotentialforadversereactions
even with short-term therapy, most pediatric ophthalmologists
and neurologists still prescribe a short course of intravenous cor-
ticosteroidsastreatmentforacuteopticneuritisinchildren,largely
basedontheresultsof theadulttrial(Cakmaklietal.,2009).Since
children were not included in the ONTT, the applicability of its
conclusionstothepediatricpatientpopulationisunknown.More-
over,theextrapolationof adultdatamaybeunsafe,andregulatory
agencies are demanding additional research in pediatrics, includ-
ingneurology,ophthalmology,andtheuseofimmunomodulating
drugs (Roberts et al., 2003;Ward and Kauffman, 2007).
While we believe that performing a clinical trial in children
with optic neuritis would be the optimal means of resolving the
problem of generalizing the adult study’s results to this patient
population,thereareseveralhurdlestoitssuccess.Aswithanyclin-
ical trial, there are medical, ethical, and practical considerations
that must be addressed. The ONTT was a three-arm study [intra-
venous (IV) methylprednisolone or oral prednisone vs. placebo],
andthetrialconcludedthatoralsteroidsshouldnotbeusedinthe
treatment of optic neuritis due to the lack of efﬁcacy in regards to
visual outcome and increased risk of recurrent disease (Beck and
Cleary, 1993; Optic Neuritis Study Group, 2008b). Given these
results, we questioned whether medical professionals would be
willing to enroll their pediatric patients in a trial with an oral
treatment arm.
In addition, trial enrollment may be threatened by the
use of a placebo arm (Caldwell et al., 2003). Intravenous
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methylprednisolone followed by oral prednisone hastened visual
recoverywithintheﬁrst6monthsafterpresentationanddecreased
the short-term (2-year) risk of MS compared to placebo;however,
steroidsdidnotalterthelong-termvisualorneurologicprognosis
(Beck et al., 1992; Optic Neuritis Study Group, 2008a,b). Never-
theless,we hypothesized that,when dealing with the loss of vision
in a child,parents would want the treatment,not placebo,arm.
Considering these factors, we performed a prospective prefer-
ence assessment. This method allows investigators to determine
factors that may inﬂuence enrollment in a clinical trial prior to
formal recruitment so that the study design could be modiﬁed as
needed(Halpern,2002).Theprimaryobjectiveofthisstudywasto
determine whether parents and medical professionals would give
consent for their children and pediatric patients, respectively, to
participate in a hypothetical study similar to the ONTT in adults.
The secondary objective was to determine whether a three-arm
trial deterred parents and medical professionals from agreeing to
participate.
MATERIALS AND METHODS
A questionnaire was administered to parents at The Children’s
Hospitalof Philadelphia(CHOP)byaresearchassistant.Aconve-
niencesampleof parentswaitingtobeseenintheOphthalmology
and Neurology clinics and on the inpatient Neurology ﬂoor was
approached, and the purpose of the study was explained. The
research assistant was available for questions but did not read or
review the questionnaire with the parent.
The questionnaire described a hypothetical situation in which
a child is diagnosed with optic neuritis and asked to participate in
a research study. The details of a randomized, masked, placebo-
controlled clinical trial for optic neuritis were described in the
format of a mock consent form. This discussion included details
of the proposed treatment arms, a description of randomization
and masking, the risks and beneﬁts associated with participating,
and a summary of the results from the ONTT in adults, as well as
the family’s alternatives to participating.
Following the presentation of this hypothetical scenario, par-
ents were asked a series of questions to assess their willingness
to enroll their child in such a clinical trial for optic neuritis.
They were ﬁrst asked about the speciﬁc trial design detailed in
the presentation, which will be referred to as the “primary trial
design,” in which the treatment arms were described as (1) IV
steroids for 3days, followed by oral steroids for 14days, (2) high-
dose oral steroids for 3days followed by low-dose oral steroids
for 14days, and (3) oral placebo for 17days. Details regard-
ing the speciﬁc corticosteroid and dosing were not speciﬁed for
the treatment arms. Subjects were asked whether or not they
would participate in the hypothetical trial by selecting “yes” or
“no,” and then provided space to document the reason for their
choice.
After this initial query, parents were also asked if they would
participate in several alternative trial designs (i.e., IV corticos-
teroids vs. placebo, without an oral arm; or IV corticosteroids vs.
oral steroids,without a placebo arm).All parents were required to
answer“yes”or“no”totheprimarytrialdesign.Unlikethefollow-
upquestionsregardingalternativetrialdesigns,“donotknow”was
not provided as an answer choice.
In addition, parents were asked three objective (true/false)
questions to assess whether they understood the information that
was presented to them regarding the design of the trial. Finally,
parents were asked about any prior experience they had partici-
pating in clinical trials and about the past medical history of their
child. Demographic or identifying information about the parent
and his or her child was not collected. Space was provided for
additional thoughts or concerns.
A similar questionnaire was distributed to adult and pediatric
ophthalmologistsandothereyecareprofessionalsattheScheieEye
Institute’s136thAnniversaryMeetingScientiﬁcProgram(May21,
2010, Philadelphia, PA, USA) and to child neurologists at CHOP
(collectively referred to as medical professionals). The question-
naire included a summary of the results from the ONTT and an
abbreviated study protocol, similar to the one given to parents.
Analogous to the parent questionnaire, medical professionals
were ﬁrst asked if they would refer a pediatric patient (<18years
of age) to participate in the proposed clinical trial with the pri-
mary trial design; however,an additional answer choice was made
available to identify those who did not see patients in a clinical
practice.Similarly,medicalprofessionalswerethenposedthesame
question for several alternative trial designs. Finally, medical pro-
fessionals were asked about their personal experience conducting
or participating in clinical trials.
Primarily, we were interested in the proportion of parents
and medical professionals who would be willing to participate
in the primary trial design; therefore, results of the question-
naire were summarized by standard descriptive measures. Given
this primary objective, if subjects failed to respond to the pri-
mary trial design question, then all subsequent responses were
excluded from further analysis, and the entire form was excluded
from our study. The secondary objective was to identify partic-
ular aspects of the proposed trial which affected the decision
to enroll a child for both parents and physicians. A subanalysis
(using a chi-square test) was performed to determine if there was
a difference in response rate among those parents whose children
had chronic medical problems, a history of corticosteroid use,
or clinical trial experience (each was examined independently,
multivariable analyses were not performed). To assess the will-
ingness to participate in alternative designs, univariate analyses
were performed comparing the distribution of responses through
95% conﬁdence intervals. All analyses were performed using
Stata 10.0.
The study was reviewed and approved by The CHOP Institu-
tionalReviewBoard.Allparticipantsverballyconsentedtopartic-
ipateinthesurvey;writtenconsentwasimpliedbycompletingthe
survey.
RESULTS
PARENTS
Atotalof 234questionnairesweredistributedtoparentsatCHOP
(120atOphthalmologyclinic,106atNeurologyclinic,and8onthe
CHOP inpatient Neurology ﬂoor). Questionnaires were returned
by 206 parents; however, the primary trial design question was
only answered by 198 parents (85% response rate; Table 1); 8 par-
tially completed questionnaires were excluded from the analysis
for insufﬁcient data.
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Afterreadingthequestionnaire,41(21%)parentswouldenroll
their child in the primary trial design, and 157 (79%) would not
participate (Table 2). Among those willing to participate, 16 par-
ents (39%) would enroll to “help his or her child” and another
three parents (7%) speciﬁcally commented that the beneﬁts out-
weighed the risks. Altruism (i.e., wanting to help other children
and advance our knowledge of the optimal treatment for optic
neuritis in children) was another reason for enrolling, cited by 11
parents(27%).Thespacetoprovideareasonforenrollingwasleft
blank by nine parents (22%). Finally, two parents (5%) cited the
additional testing and monitoring that children in the trial would
receive as the reason to participate.
Of the 157 parents who declined enrollment,34 parents (22%)
cited the risk/beneﬁt ratio and an additional 27 (17%) reported
the medication side effects as the primary reason. Factors related
to the child’s health were named by 23 parents (15%), includ-
ing a few parents who thought their children were too young or
that their current medical conditions would make them ineligible
for the study. Others stated that they would only consider trials
Table 1 | Baseline characteristics.
No. of forms
distributed
No. of forms
completed
Response
rate (%)
LOCATIONWHERE PARENTSWEREAPPROACHED
Ophthalmology out-patient clinic 120 104 87
Neurology out-patient clinic 106 89 84
Neurology inpatient clinic 8 5 63
All locations 234 198 85
SPECIALTY OF SURVEYED PHYSICIAN
Ophthalmology 50 30 60
Neurology 30 19 63
All specialties 80 49 61
for life-threatening conditions. There were 18 parents (11%) who
wantedtodiscussthetrialwiththeirownphysicianoranotherspe-
cialist; therefore, they declined enrollment. The placebo arm was
a factor for 16 parents (10%). While ﬁve parents were opposed
to their children receiving the placebo, 11 parents declined the
study because of the favorable outcome of the placebo group.
For the remaining parents, 14 (9%) did not provide a reason for
declining to participate, 11 (7%) did not want their children to
be randomized (and would prefer they or their doctor picked the
treatment), 8 (5%) required more research, and 6 (4%) opposed
the participation of their children in research.
When all parents were asked if they would enroll their children
if their doctor recommended it, 85 (43%) would participate, 45
(23%) would not participate, 64 (32%) were unsure, and 5 (3%)
did not answer the question (Table 2). Of the 157 parents who
initially refused enrollment, 49 (31%) responded that they would
participate if their doctor recommended it, 42 (27%) would not
participate,55(35%)wereuncertain,and11(7%)didnotrespond
to the question.
Regarding the medical history of their child, 82 (41%) parents
responded that their child had a chronic medical condition. The
condition was speciﬁed by 73 parents, with the most common
being seizures/epilepsy (11),optic glioma/neuroﬁbromatosis type
1 (9), brain tumor (4), and asthma (4). In addition, speciﬁc ques-
tionsaddressedwhetherthechildhadademyelinatingdisease,and
a small subset of parents reported a history of optic neuritis (2),
MS (1), or acute disseminated encephalomyelitis (1). Of the 188
parentswhoanswered,mostparentsrespondedthattheirchildren
were naive to IV and oral forms of steroids, 162 (86%) and 139
(74%),respectively,and139outof 189whoresponded(74%)had
never been asked to participate in a clinical trial.
Analysis of baseline characteristics did not identify any statisti-
cally signiﬁcant associations with willingness to participate in the
primarytrialdesign:priorclinicaltrialexperience(p=0.07),child
T a b l e2|P a r ental willingness to participate.
Number
responding
Yes (95% CI) % No (95% CI) % Do not know
(95% CI)
%
PRIMARYTRIAL DESIGN
Would you enroll your child in this study? 198 41 (30, 52) 21 157 (146, 168) 79 N/A N/A
If my doctor recommended it, I would enroll in this trial 186 84 (71, 97) 45 43 (32, 54) 23 59 (47 , 71) 32
ALTERNATIVETRIAL DESIGNS
If my child had a numb leg instead of poor vision, I would
enroll in this trial
187 14 (7 , 21) 7 108 (95, 121) 58 65 (52, 78) 35
If the treatment options were IV steroids vs. placebo (but
not oral steroids), I would enroll in this study
186 16 (9, 23) 9 125 (112, 138) 67 45 (34, 56) 24
If the treatment options were IV steroids vs. oral steroids
(but not placebo), I would enroll in this study
186 26 (17 , 35) 14 117 (104, 130) 63 43 (32, 54) 23
If all children got IV steroids (but differed only in the
number of days of treatment), I would enroll in this study
186 26 (17 , 35) 14 115 (102, 128) 62 45 (34, 56) 24
If the treatment options were similar to the adult study:
high-dose steroids (IV) vs. low-dose steroids (oral) vs.
placebo, I would enroll in this study
186 18 (10, 26) 10 123 (110, 136) 66 45 (34, 56) 24
N/A=not applicable; “Do not know” was not given as an answer choice.
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with chronic medical condition (p=0.16), prior treatment with
IVsteroids(p=0.12)ororalsteroids(p=0.15),orclinicalsetting
(ophthalmology vs. neurology, p=0.37).
In response to three objective questions to determine if par-
ents understood the clinical trial design,188 responded to at least
two questions. All three questions were answered correctly by 126
parents, and two out of three questions were answered correctly
by an additional 22 parents (79% combined, Table 3). Correctly
answering all three objective questions was not associated with
willingness to participate in the primary trial design (p=0.49).
Responses to a series of questions about alternative trial designs
Table 3 | Objective question responses.
True/false
questions
Number
responding
True (%) False (%) Do not
know (%)
In a randomized
double-blind trial,
the physician
picks the
treatment that my
child receives
188 20 (11) 151 (80) 17 (9)
A placebo is a
sugar pill
189 183 (97) 1 (1) 5 (3)
If I enrolled in the
above trial
(primary trial
design), my child
would have a 1/3
chance of being
on no medication
184 143 (78) 21 (11) 20 (11)
Bold/underline=correct answer.
are presented in Table 2. Overall, the willingness to participate
decreased for all alternative study designs.
MEDICAL PROFESSIONALS
Questionnairesweredistributedto80physiciansandeyecarepro-
fessionals and 49 were returned at least partially completed (61%
response rate; Table 1). Over half of responding medical profes-
sionals (57%) had experience conducting a clinical trial in some
capacity.Fortheprimarytrialdesign,43medicalandeyecarepro-
fessionals (98%) would refer their pediatric patients for the trial,
and 1 (2%) declined (Table 4). For each of the proposed alterna-
tive trial designs, 43 responses were received (Table 4). Similar to
the parent questionnaire, the willingness to participate decreased
for all alternative study designs.
DISCUSSION
Inthisstudyweadministeredaquestionnairetoassessthewilling-
nessofparentsandmedicalprofessionalstoparticipateinaclinical
trial for acute optic neuritis in the pediatric population. Results
from a hypothetical trial conﬁrming the willingness to participate
in the study support the likelihood of participating in the actual
trial(Halpernetal.,2001).Whilemedicalprofessionalswereover-
whelmingly supportive of a three-arm Pediatric ONTT, parents
were less likely to give consent for the participation of their chil-
dren. Compared to adult trials, recruitment for pediatric studies
has proven to be more difﬁcult (Caldwell et al.,2003).
Prospective preference assessment was an effective method to
gather pretrial data that will inﬂuence its future design. First, the
proportion of parents willing to participate in a trial is critical to
calculate the sample size for such a trial to achieve optimal power.
These results will be used to minimize under enrollment, which
would threaten the trial’s validity. Second, the willingness to par-
ticipatedidnotincreasewhenalternatestudydesigns(forexample,
without a placebo or oral arm) were proposed. Third,the support
Table 4 | Medical professional willingness to participate.
Number
responding
Yes
(95% CI)
%N o
(95% CI)
% NotApplicable (i do not
see patients) (95% CI)
%
PRIMARYTRIAL DESIGN
If a child (<18years old) presents with acute optic
neuritis, I would refer him or her to participate in the
proposed clinical trial
49 43 (39, 48) 88 1 (−1, 3) 2 5 (1, 9) 10
ALTERNATIVETRIAL DESIGNS
If a child had a numb leg instead of poor vision, I would
refer him or her to participate in this trial
43 25 (19, 31) 58 6 (2, 10) 14 12 (6, 18) 28
If the treatment options were IV steroids vs. placebo (but
not oral steroids), I would refer my patients for this trial
43 31 (25, 37) 72 6 (2, 10) 14 6 (2, 10) 14
If the treatment options were IV steroids vs. oral steroids
(but not placebo), I would refer my patients for this trial
43 28 (22, 34) 65 9 (4, 14) 21 6 (2, 10) 14
If all children got IV steroids (but differed only in the
number of days of treatment), I would refer my patients
for this trial
43 35 (30, 40) 81 5 (1, 9) 12 3 (0, 6) 7
If the treatment options were the same as the ONTT
[high-dose steroids (IV) vs. low-dose steroids (oral) vs.
placebo], I would refer my patients for this trial
43 26 (20, 32) 60 7 (2, 12) 16 10 (5, 15) 23
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of medical professionals is important to a parent in the decision
to enroll.
While we hypothesized that the speciﬁcs of the design of this
hypothetical study (i.e., a three-arm trial) would inﬂuence the
decision to enroll, parental consent was determined by the same
factors that affect any trial. The likelihood of enrolling in a trial is
most often determined by the risk/beneﬁt ratio (Tait et al., 2004).
Asagroup,therisk/beneﬁtratiowasthemostcommonreasonfor
parents’ decision to enroll or decline participation in this study.
Altruism is another common reason for participating in trials
(Tait et al., 2003) whereas concern regarding the randomization
and masking (blinding) processes are often deterrents for parents
(Caldwell et al.,2003; Gross et al.,2006). These explanations were
also commonly cited by parents in this study as the rationale for
their decision.
Mostparentscorrectlyunderstoodtheimplicationsofrandom-
ization, masking, and the use of a placebo, which were assessed
using true/false questions to verify understanding of the concepts.
Nevertheless, these factors present challenges in trial recruitment
(Caldwelletal.,2003;Grossetal.,2006).Whiletheuseof aplacebo
arm is often a concern limiting trial enrollment,some families did
not want their children exposed to corticosteroids and seemed to
prefer no treatment.Additional trials were proposed to determine
if enrollment would improve, for example, without a placebo or
oral arm; however, parents and physicians were not more willing
to participate in alternate study designs.
Atrialassessingparesthesias,insteadofvisionloss,wasposedto
assess whether willingness to enroll would increase. This trial was
proposed as the symptom may be considered more benign with
decreasedrisk;however,neurologistscommentedthatparesthesias
may be due to spinal cord lesions; therefore, as a group, medical
professionals were less likely to enroll their patients in such a trial.
Forthealternativequestions,allparticipantsweregiventheoption
of selecting “do not know” as an answer choice. This option was
notgivenfortheprimarytrialdesignsinceadeﬁnitiveanswer(yes
or no) would be required for the actual trial. It is unclear how this
option (“do not know”) would have affected the outcome of the
primary trial design.
The willingness to participate in a pediatric ONTT similar
to the adult study doubled with a medical professional’s recom-
mendation. Previous studies have shown that approval from a
physician impacts enrollment in clinical trials (Harth and Thong,
1995; Langley et al., 1998; Caldwell et al., 2003; Nabulsi et al.,
2011). In addition to trust in the medical system, this increase in
enrollment may be due to the shared responsibility for the child’s
health between the physician and parent (Tait et al.,2003).With a
physician’sconsent,aparentmayfeelrelievedof theburdenof the
decision to enroll in a clinical trial (Zupancic et al., 1997; Langley
et al., 1998; Singhal et al., 2002; Shilling and Young, 2009). Physi-
cian recommendation is likely to enhance enrollment in a future
pediatricONTT;however,ourmotivationforaskingthisquestion
was not to exploit the vulnerability of parents in the informed
consent process. Instead, this underscores the importance of hav-
ing the support of referring medical professionals when designing
clinical trials, as these clinicians may impact a trial’s success.
There are a number of limitations to this study. Demographic
data was not collected. For the actual trial,recruitment would tar-
get all racial, ethnic, religious, and socioeconomic backgrounds;
therefore, demographic data was not felt to provide additional
insight regarding the willingness to enroll. Parents presenting to
neurology and ophthalmology clinics in a single academic cen-
ter were targeted; this convenience sample may not reﬂect the
opinions of all parents. However, the institution is a tertiary care
center which not only serves the community but also has a large
referral base.
A mock consent form was used to assess the willingness to
enroll as opposed to a structured interview with a research assis-
tant. The latter has been shown to inﬂuence the willingness to
enroll (Tait et al., 2003). Furthermore, the consent form is often
intimating to parents and may alter their decision to participate
after verbally agreeing to enroll (Pierro and Spitz, 1997). Since a
research assistant and verbal explanation may increase the likeli-
hood of enrolling, the use of a mock consent form rather than a
researchassistantmayresultinanunderestimateofthewillingness
to enroll.
Using the method of prospective preference assessment, this
study provided valuable insight into parent and medical pro-
fessional interest in a hypothetical trial for children with optic
neuritis.Theseresultswillimprovethedesignof afuturePediatric
ONTT.
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